Reach Us +44 330 818 7254


Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Current Status Of Weight Loss Medications And Therapeutic Interventions: A Pharmacologist's Approach | 14813
ISSN: 2165-7904

Journal of Obesity & Weight Loss Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

25th Global Obesity Meeting

Rome, Italy

19th Euro Obesity and Endocrinology Congress

Barcelona, Spain
Google Scholar citation report
Citations : 1582

Journal of Obesity & Weight Loss Therapy received 1582 citations as per Google Scholar report

Journal of Obesity & Weight Loss Therapy peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • Genamics JournalSeek
  • Centre for Agriculture and Biosciences International (CABI)
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • CABI full text
  • Cab direct
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • University of Bristol
  • pubmed
Share This Page

Current status of weight loss medications and therapeutic interventions: A pharmacologist's approach

2nd International Conference and Exhibition on Obesity & Weight Management

Kiran V. Barar

ScientificTracks Abstracts: J Obes Weight Loss Ther

DOI: 10.4172/2165-7904.S1.010

Obesity threatens the overall well-being of patients and is a major public health concern. It is basically a consequence of excess adipose tissue getting accumulated in the adipocytes (fat cells). The number of adipocytes is usually constant in an individual but when such individual become obese, the content of each cell multiplies and can increase in size up to100 times. The body mass index, i.e., BMI, calculated as weight (kg) divided by height (m 2 ), is a continuous, although imperfect, measure of body fatness and can be readily and reliably quantified in clinical settings. The BMI correlates with total body fat (TBF) as well, which is estimated using dual energy X-ray absorptiometry (DEXA) scanning in overweight and obese individuals. The BMI exceeds 30 kg/m 2 at any age group in case of obesity. Anti-obesity medications or weight loss drugs are the pharmacological agents which reduce and/or control body weight. These drugs alter one or the other fundamental processes (appetite, metabolism, absorption of calories, etc.) of the human weight control mechanisms. Orlistat was the only anti-obesity medications approved by the FDA for long term use. It reduces intestinal fat absorption by inhibiting pancreatic lipase. Rimonabant, a second drug, works via a specific blockade of the endocannabinoid system. But due to safety concerns, it never got USFDA-approval. Sibutramine which acts in the brain to inhibit deactivation of the neurotransmitters, thereby decreasing appetite was also withdrawn from the US and Canadian markets in October 2010 due to cardiovascular risks. Finally in last 13 years, in June?2012, US regulators approved the first drug called lorcaserin to treat obesity. Lorcaserin was approved for obese adults who have high blood pressure, high cholesterol or type 2 diabetes, and is to be used in combination with a low-calorie diet and exercise. Also recently in July?2012, USFDA has approved extended-release phentermine plus topiramate (marketed as Qsymia) in the form of an add-on therapy along with low-calorie diet and exercise for the long term management of overweight and/or obese adults. There are so many other medications (will be discussed for their present status on the conference podium), all of which are proposed to have anti-obesity effects but because of potential side effects, it is recommended that they should only be prescribed for obesity where it is hoped that the benefits of the treatment outweigh its risks. Another strategy to prevent obesity explored in the dietary industry is many kinds of fat substitutes. Because an uncontrolled diet and a lack of exercise (the most common causes of obesity) there are some fairly simple treatments for obesity. To incorporate more natural foods into the diet, to drink more water, to cut-out junk food and to get into the habit of exercising several times every week, we can drastically lower our weight and decrease the chances of becoming obese. If there are some disease like hypothyroidism, specific medications are needed that can help regulate the thyroid gland and improve the rate of metabolism. Lastly, I would say to find out the causes of obesity and then go for the treatment and prevention. However the main treatment modalities for overweight and obese individuals remain dieting and physical exercise and not the intake of medicines.